Kangmei Pharmaceutical Co., Ltd. (600518 CH) Layout in the Entire Industrial Chain of Traditional Chinese Medicine

Shanghai | Pharmaceutical | Company report

Steady Growth of Performance

Kangmei Pharmaceutical is a large modern medical resource-based enterprise and a national key high-tech enterprise with the production of traditional Chinese medicinal decoction pieces as its core and the businesses covering the entire industrial chain of traditional Chinese medicine. By virtue of rich resource layouts and channel advantages and so on, company revenue and net profit from 2001 to 2013 were recorded with the compound growth of respectively 30%+ and 40%+. Since 2014, the company has continued its steady and robust growth, mainly benefiting from the high increases of traditional Chinese medicinal decoction pieces, western medicine trade and health products and food businesses.


Kangmei has basically penetrated the upstream, midstream and downstream industries of the industrial chain of traditional Chinese medicine, up to medicinal herb cultivation and trade, down to production and development and terminal sale, which is gradually forming the control of the resources and circulation market of traditional Chinese medicinal herbs, and enjoys the advantage with its leading position in the same trade, and may obtain a certain right to speak in the field of traditional Chinese medicine.

The company has built a multi-channel marketing network. Kangmei has become the second listed pharmaceutical enterprise involved in direct marketing, plus the professional advantage of its direct marketing group. It is expected that the direct marketing channel will realize geometric growth, up to above one billion. In addition, e-commerce business of the company also steps into a fast lane, further forming an all-round sale pattern, which is expected to boost the acceleration in the growth of various businesses.

Valuation stands at a low level compared to the peer

The company possesses an advantage of the entire industrial chain of traditional Chinese medicine. The capacity bottleneck of decoction pieces is gradually being eliminated, downstream consumer products have a rapid increase, and e-commerce platforms will also provide channel support, which make continuous growth hopefully. Currently, its valuation corresponding to the performance of 2014 is less than 15 times, a low point in the industry. We grant it 18X 2014EPS, and the target price can be CNY 19.80, with "Buy" rating initially.

Historical P/E Valuation



Source: Bloomberg, Phillip Securities (HK) Research



23 December 2014

BUY (Initially)

CMP CNY16.22 TARGET CNY19.80 (+22%)

COMPANY DATA	
O/S SHARES (MN):	2,199
MARKET CAP (CNYMN) :	35,663
52 - WK HI/LO (CNY):	19.71/ 13.80

SHARE HOLDING PATTERN, %			
Kang Mei Industrial	Co. Ltd. :	30.42	

PRICE PERFORMANCE, %				
	1个月	3个月	1年	
Kangmei	5.32	4.98	-8.10	
HS300	-26.08	-37.68	-57.09	



Source: Phillip Securities (HK) Research

KEY FINANCIALS

CNY mn	FY12	FY13	FY14E	FY15E
Net Sales	11107	13263	16225	19476
Net Profit	1441	1880	2418	3050
EPS, CNY	0.66	0.86	1.10	1.39
PER, x	24.76	18.97	14.75	11.69
BVPS, CNY	4.81	5.47	6.31	7.37
P/BV, x	3.37	2.97	2.57	2.20
ROE, %	14.54	16.63	18.67	20.28
Debt/Equity (%)	69.69	84.96	73.91	73.91


Source: Company reports, Phillip Securities Est.

Fan Guohe (+ 86 21 51699400-110) fanguohe@phillip.com.cn

PhillipCapital

Steady Growth of Performance

As shown in the third-quarter report in 2014 of Kangmei Pharmaceutical, the recorded business revenue in this period was CNY 11.577 billion yuan, with the year-on-year growth of 22.16%; the net profit belonging to shareholders of the listed company was 1.498 billion yuan, with the year-on-year increase of 8.02% and the earnings per share of 0.681 yuan; and net profit excluding non-recurring items was 1.482 billion yuan, with the year-on-year rise of 7.53%. It is worth mentioning that on October 10, the company got again the notice about the continuation of high-tech enterprise. If it is estimated with a tax rate of 15%, the company's net profit, in fact, increases at an annual rate of 22%, maintaining a relatively high growth speed.



Source: Company, Phillip Securities (HK) Research

Specifically, the company's traditional Chinese medicinal decoction pieces, Western medicine trade and health food businesses have realized high increases. Firstly, the revenue of the traditional Chinese medicinal decoction pieces in the first three quarters had a year-on-year rise of 50%, continuing the growth acceleration compared with the increase of 39% in the first half year. At present, Beijing production base of traditional Chinese medicinal decoction pieces has acquired GMP certificate. It is expected that the capacity of 6,000 tons will be put into production successively. Bozhou base and other bases are also handling procedures such as production authentication. Secondly, benefiting from hospital pharmacy trusteeship, the revenue of Western medicine trade business had a year-on-year increase exceeding 80%. Thirdly, the revenue growth of health products was about 100%. The direct marketing business of the company in cooperation with the PICC was offically launched, with the revenue contribution being over 200 million yuan in the first three quarters.


Meanwhile, the company's profitability remained steady, the combined gross margin reduced by 0.15 percentage points, marketing expense ratio basically kept balance, management fee rate reduced by 0.23 percentage points and financial fee rate increased by 0.24 percentage points.

Layout of the Entire Industrial Chain of Traditional Chinese Medicine

In recent years, Kangmei has actively implemented a strategy of the entire industrial chain of traditional Chinese medicine and has begun to take shape, occupying a leading position in the sector. The company has built GAP and standardized planting bases with an area exceeding 50 thousand mu in Yunnan, Sichuan, Jilin, Gansu and so on, involving pseudo-ginseng and Panax ginseng, etc. And it has set up nine production bases of traditional Chinese medicinal decoction pieces in Guangdong,



Beijing, Shanghai, Sichuan, Jilin, Anhui, Gansu and so forth. Thus, a nationwide production layout is basically completed.



Source: CNBS, Company, Phillip Securities (HK) Research

In addition, the company has merged and acquired professional markets of traditional Chinese medicinal herbs in Bozhou, Anhui, etc., the newly-built national largest Kangmei (Bozhou) Huatuo International Chinese Medicine City has been put into use, and currently the company has managed the professional trading markets of traditional Chinese medicine which occupy over 75% of the national trading volume. At the same time, the company newly builds Kangmei Hospital, merges and acquires and integrates many domestic public hospitals, and trusts nearly one hundred hospital pharmacies. Furthermore, it invests the construction of Ophiocordyceps Sinensis Global Trading Center in Xining, Qinghai Province and builds Sino-ASEAN Kangmei Yulin Chinese Medicinal Herbs (Spices) Trading Center in Yulin, Guangxi Province. Generally speaking, Kangmei Pharmaceutical has basically penetrated the upstream, midstream and downstream industries of the industrial chain of traditional Chinese medicine, up to medicinal herb cultivation and trade, down to production and development and terminal sale, which is gradually forming the control of the resources and circulation market of traditional Chinese medicinal herbs, and may obtain a certain right to speak in the field of traditional Chinese medicine.

Build A Multi-Channel Marketing Network

Apart from traditional channels, the company also obtains national direct marketing business license and becomes the second listed pharmaceutical enterprise involved in direct marketing. In light of the rarity of direct marketing license, the company's direct marketing group possesses professional advantages. We expect that its direct marketing channel is hopeful to realize geometric growth, achieving a level of over one billion yuan.

Meanwhile, the e-commerce business of the company also steps into a fast lane. Since a large trading platform of traditional Chinese medicinal herbs (e Medicine Valley) was launched online, depending on more than 30 warehousing logistics centers nationwide, the company has established nearly 20 standards of listed variety, with the business electron plate reaching over 10 billion yuan. Meanwhile, subsidiary "Kangmei Mall" and O2O trading platform of traditional Chinese medicinal herbs "Kangmei Chinese Medicine City" have also been put into operation online. Generally speaking, the company has constituted an all-round sale pattern including hospital direct supply, OTC selling, wholesale distribution, chain store selling, terminal retail, e-commerce, direct marketing and so on, which is expected to boost the acceleration of the growth of various businesses.



Catalyst

Newly-added capacity of traditional Chinese medicinal decoction pieces is released rapidly;

The growth in the fields of health products and foods exceeds expectations; The expansion of direct marketing channel is faster than expectation.

Risks

The trading business of medicinal herbs has excessively great demand for cash flow; The scale of projects in process is enormous.



Financials

Periodicity:	2011	2012	2013	2014F	2015F
Valuation Ratios					
Price Earnings	34.81	24.76	18.97	14.75	11.69
Price to Book	3.86	3.37	2.97	2.57	2.20
Dividend Yield	0.31%	1.23%	1.60%	2.03%	2.57%
Per share data(CNY)					
EPS Adjusted	0.47	0.66	0.86	1.10	1.39
Book Value Per Share	4.21	4.81	5.47	6.31	7.37
Dividends Per Share	0.05	0.20	0.26	0.33	0.42
Growth & Margin					
Revenue growth		83.49%	19.41%	22.33%	20.04%
Gross profit growth		51.92%	23.44%	25.78%	23.86%
Net profit growth		43.40%	30.43%	28.65%	26.10%
Gross Margin	29.87%	24.73%	25.56%	26.29%	27.12%
Operating Margin	21.42%	17.67%	18.75%	19.49%	20.32%
Net Profit Margin	16.60%	12.98%	14.17%	14.91%	15.66%
Dividend Payout Ratio %	10.73%	30.53%	30.41%	30.00%	30.00%
Key ratios					
Return on Assets	8.57%	8.68%	9.35%	10.43%	11.66%
Return on Equity	14.18%	14.54%	16.63%	18.67%	20.28%
Liability ratio	39.31%	41.07%	45.93%	42.50%	42.50%
Effective Tax Rate	14.84%	14.84%	15.07%	15.00%	15.00%
Income Statement(CNY: mn) Revenue	6,053	11,107	13,263	16,225	19,476
- Cost of Goods Sold	4,245	8,361	9,873	11,960	14,194
Gross Income	1,808	2,747	3,391	4,265	5,282
- Selling, General & Admin Ex	512	784	904	1,103	1,324
Operating Income	1,297	1,963	2,486	3,161	3,958
- Interest Expense	269	360	406	460	529
- Net Non-Operating Losses (-153	-91	-134	-145	-160
Pretax Income	1,180	1,693	2,214	2,846	3,589
- Income Tax Expense	175	251	334	427	538
Income Before XO Items	1,005	1,441	1,880	2,419	3,051
- Minority Interests	0	0	1	1	1
Net Profit	1,005	1,441	1,880	2,418	3,050

Source: Company, Phillip Securities (HK) Research Estimates



Kangmei Pharmaceutical (600518 CH) Company report

Total Return	Recommendation	Rating	Remarks
>+20%	Buy	1	>20% upside from the current price
+5% to +20%	Accumulate	2	+5% to +20% upside from the current price
-5% to +5%	Neutral	3	Trade within $\pm 5\%$ from the current price
-5% to -20%	Reduce	4	-5% to -20% downside from the current price
<-20%	Sell	5	>20% downside from the current price

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

GENERAL DISCLAIMER

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

Disclosure of Interest

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

Availability

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.

© 2014 Phillip Securities (Hong Kong) Limited

Contact Information (Regional Member Companies)



Kangmei Pharmaceutical (600518 CH) Company report

SINGAPORE

Phillip Securities Pte Ltd Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel : (65) 6533 6001 Fax : (65) 6535 6631 Website: www.poems.com.sg

HONG KONG Phillip Securities (HK) Ltd

Exchange Participant of the Stock Exchange of Hong Kong 11/F United Centre 95 Queensway Hong Kong Tel (852) 22776600 Fax (852) 28685307 Websites: <u>www.phillip.com.hk</u>

INDONESIA

PT Phillip Securities Indonesia ANZ Tower Level 23B,

Jl Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel (62-21) 57900800 Fax (62-21) 57900809 Website:www.phillip.co.id

THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel (66-2) 6351700 / 22680999 Fax (66-2) 22680921 Website<u>www.phillip.co.th</u>

UNITED KINGDOM

King & Shaxson Capital Limited 6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel (44-20) 7426 5950 Fax (44-20) 7626 1757 Website: www.kingandshaxson.com

AUSTRALIA

PhillipCapital Australia Level 12, 15 William Street, Melbourne, Victoria 3000, Australia Tel (613) 96188238 Fax (613) 92002272 Website: www.phillipcapital.com.au

MALAYSIA

Phillip Capital Management Sdn Bhd B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel (603) 21628841 Fax (603) 21665099 Website: www.poems.com.my

JAPAN

PhillipCapital Japan K.K. Nagata-cho Bldg., 8F, 2-4-3 Nagata-cho, Chiyoda-ku, Tokyo 100-0014 Tel (81-3) 35953631 Fax (81-3) 35953630 Website:<u>www.phillip.co.jp</u>

CHINA

Phillip Financial Advisory (Shanghai) Co. Ltd No 436 Hengfeng Road, Greentech Unit 604, Postal code 200070

Tel (86-21) 51699400 Fax (86-21) 63532643 Website: <u>www.phillip.com.cn</u>

FRANCE

King & Shaxson Capital Limited 3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel (33-1) 45633100 Fax (33-1) 45636017 Website: www.kingandshaxson.com

UNITED STATES Phillip Futures Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1.312.356.9000 Fax +1.312.356.9005